Research Grant: Page 2

Neurofilament light blood test shows concussion damage in study of veterans

Sponsored by grant funding from the U.S. Department of Defense (DOD) Chronic Effects of Neurotrauma Consortium (CENC), the study evaluated levels of the protein NfL in blood tests and how they correlated with concussion in 195 military veterans. Researchers found higher levels in veterans with a history of three or more concussions compared to those who had not had mTBI. In addition, high NfL was associated with more severe symptoms such as post-traumatic stress disorder (PTSD) and depression.

May 27, 2020

Fluxergy invests $30M to produce more point-of-care SARS-CoV-2 tests

The Fluxergy Analyzer test system, which uses polymerase chain reaction (PCR) and microfluidics technology, identified the SARS-CoV-2 virus in less than one hour during bench lab validation studies conducted by the company and in an analysis of patient samples conducted by scientists at the University of California, San Diego (UCSD).

May 12, 2020

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents

The latest allowances mark MilliporeSigma's 25th and 26th CRISPR patents worldwide and the fourth in the U.S. The company is in discussions to license the foundational technology for therapeutic uses and is seeking collaboration partners for research and development.

May 10, 2020

Abbott's 'lightning fast' coronavirus test takes center stage in U.S. pandemic strategy

The U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) for the polymerase chain reaction (PCR) molecular POC test on March 27. The assay provides positive results in as little as five minutes and negative results in 13 minutes, according to the company.

March 29, 2020

Luminex coronavirus panel gets FDA emergency authorization

The NxTag test is designed for use at high complexity laboratories on Luminex' Magpix system, which can handle specimens for up to 96 patients, with results available in approximately four hours, according to the company. Luminex noted that labs can run the CoV test alongside the company's respiratory pathogen panel, which allows differentiation of the new virus from other diseases that have similar symptoms.

March 26, 2020

Qiagen boosts RNA extraction kit production

The company plans to reach a global capacity to produce RNA extraction kits to support more than 6.5 million patient tests per month by the end of April, 10 million per month by the end of June, and 20 million per month by the end of the year. It expects to receive the European CE-IVD Mark for the kit soon and is also working with the U.S. Food and Drug Administration (FDA) to secure emergency use authorization (EUA) in the U.S.

March 17, 2020

Most Popular

Genetic causes identified for three rare diseases

Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease

SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests

Duke University researchers discover biomarkers may identify early pancreatic cancer risk

Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics

Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition

Fusion Genomics secures $1M U.S. to study respiratory infections panel

The Consortium Québécois sur la Découverte du Medicament (CQDM) is a Montreal-based biomedical research consortium that funds new technologies with potential value in facilitating drug discovery and development. The organization noted that since it was founded in 2008, it has raised more than $118 million Canadian ($90 million U.S.) through Canadian government programs and a wide range of pharmaceutical industry partners, including Merck, Pfizer, AstraZeneca, and Eli Lilly.

January 9, 2020

FDA awards $20M to DNAnexus to enhance cloud-based research portal

Launched in 2015, the precisionFDA project is a hub for information sharing in bioinformatics approaches and regulatory science surrounding precision approaches for drugs and devices.

December 3, 2019

Cheap vaginal-fluid testing signals risk for premature birth

The study involved noninvasive testing of 340 women in midtrimester pregnancy, with the goal of identifying two important signs of risk for preterm birth: depletion of Lactobacillus bacteria in the vaginal microbiome and short cervical length, defined as 25 mm. It was funded by grants from the Bill & Melinda Gates Foundation, the Brazilian Ministry of Health, and the Brazilian National Research Council.

October 21, 2019

FYR gets NIH small business grant for epilepsy diagnostics

The grant was awarded by the NIH's National Institute of Neurological Disorders and Stroke, through the government's Small Business Innovation Research program. In the first phase of the funding, FYR Diagnostics will develop biomarkers for use in diagnostic kits.

October 9, 2019

Thermo Fisher flags data for tumor mutation test

Tumor mutational burden refers to the number of mutations in cancer cells. It has been emerging as a biomarker for response to checkpoint immunotherapies, including drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), though its role is still not well understood.

September 5, 2019

NIH-funded studies aim to get to the bottom of depression, suicide

The NIMH has jointly awarded a $3.6 million grant to investigate the potential for a blood test for suicide risk to researchers at the Van Andel Institute in Grand Rapids, MI; Pine Rest Christian Mental Health Services, also of Grand Rapids; and Columbia University in New York City. The grant money will be used over five years to study inflammatory mechanisms associated with suicide risk, based on research by Dr. Lena Brundin, PhD (Van Andel); Dr. Eric Achtyes (Pine Rest); and Dr. J. John Mann (Columbia).

August 28, 2019

Previous Page

Page 2 of 3

Next Page